Barclays’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.4M | Buy |
76,540
+41,087
| +116% | +$9.6M | ﹤0.01% | 1121 |
|
|
2026
Q1 | $8.11M | Buy |
35,453
+24,209
| +215% | +$5.43M | ﹤0.01% | 1560 |
|
|
2025
Q4 | $2.4M | Buy |
11,244
+462
| +4% | +$95.4K | ﹤0.01% | 2805 |
|
|
2025
Q3 | $2.14M | Sell |
10,782
-1,147
| -10% | -$214K | ﹤0.01% | 2840 |
|
|
2025
Q2 | $2.06M | Buy |
11,929
+1,539
| +15% | +$251K | ﹤0.01% | 2825 |
|
|
2025
Q1 | $1.62M | Sell |
10,390
-18,586
| -64% | -$2.65M | ﹤0.01% | 2792 |
|
|
2024
Q4 | $3.99M | Buy |
28,976
+10,240
| +55% | +$1.35M | ﹤0.01% | 2364 |
|
|
2024
Q3 | $2.8M | Sell |
18,736
-268
| -1% | -$36.2K | ﹤0.01% | 2573 |
|
|
2024
Q2 | $2.59M | Sell |
19,004
-2,068
| -10% | -$281K | ﹤0.01% | 1955 |
|
|
2024
Q1 | $3.19M | Buy |
21,072
+3,747
| +22% | +$535K | ﹤0.01% | 2171 |
|
|
2023
Q4 | $2.18M | Sell |
17,325
-157
| -0.9% | -$15.7K | ﹤0.01% | 2848 |
|
|
2023
Q3 | $1.64M | Buy |
17,482
+16,874
| +2,775% | +$1.58M | ﹤0.01% | 2008 |
|
|
2023
Q2 | $54.3K | Sell |
608
-68,294
| -99% | -$5.94M | ﹤0.01% | 3807 |
|
|
2023
Q1 | $7.39M | Buy |
68,902
+12,195
| +22% | +$1.4M | ﹤0.01% | 1309 |
|
|
2022
Q4 | $6.93M | Sell |
56,707
-68,114
| -55% | -$7.91M | ﹤0.01% | 1414 |
|
|
2022
Q3 | $12.9M | Sell |
124,821
-20,223
| -14% | -$1.92M | 0.01% | 767 |
|
|
2022
Q2 | $13.5M | Buy |
145,044
+144,179
| +16,668% | +$13.6M | 0.01% | 883 |
|
|
2022
Q1 | $102K | Buy |
865
+238
| +38% | +$27.6K | ﹤0.01% | 3768 |
|
|
2021
Q4 | $84K | Sell |
627
-34,082
| -98% | -$5.07M | ﹤0.01% | 3764 |
|
|
2021
Q3 | $5.53M | Buy |
34,709
+34,024
| +4,967% | +$4.66M | ﹤0.01% | 1558 |
|
|
2021
Q2 | $90K | Sell |
685
-3,354
| -83% | -$447K | ﹤0.01% | 3884 |
|
|
2021
Q1 | $520K | Sell |
4,039
-298
| -7% | -$45.3K | ﹤0.01% | 3159 |
|
|
2020
Q4 | $723K | Buy |
4,337
+216
| +5% | +$35.7K | ﹤0.01% | 2987 |
|
|
2020
Q3 | $636K | Buy |
4,121
+138
| +3% | +$19.8K | ﹤0.01% | 3048 |
|
|
2020
Q2 | $589K | Buy |
3,983
+3,654
| +1,111% | +$502K | ﹤0.01% | 3207 |
|
|
2020
Q1 | $37K | Sell |
329
-49
| -13% | -$6.37K | ﹤0.01% | 5386 |
|
|
2019
Q4 | $52K | Sell |
378
-8,233
| -96% | -$915K | ﹤0.01% | 5726 |
|
|
2019
Q3 | $829K | Buy |
8,611
+8,313
| +2,790% | +$927K | ﹤0.01% | 3833 |
|
|
2019
Q2 | $34K | Sell |
298
-9,313
| -97% | -$1.11M | ﹤0.01% | 6248 |
|
|
2019
Q1 | $1.13M | Sell |
9,611
-11,022
| -53% | -$965K | ﹤0.01% | 3279 |
|
|
2018
Q4 | $1.29M | Buy |
20,633
+15,613
| +311% | +$981K | ﹤0.01% | 2853 |
|
|
2018
Q3 | $356K | Buy |
5,020
+137
| +3% | +$9.43K | ﹤0.01% | 4549 |
|
|
2018
Q2 | $325K | Sell |
4,883
-377
| -7% | -$24.8K | ﹤0.01% | 4318 |
|
|
2018
Q1 | $345K | Buy |
5,260
+560
| +12% | +$31.5K | ﹤0.01% | 4334 |
|
|
2017
Q4 | $188K | Sell |
4,700
-300
| -6% | -$10.9K | ﹤0.01% | 4740 |
|
|
2017
Q3 | $181K | Buy |
+5,000
| New | +$143K | ﹤0.01% | 4509 |
|
Other funds holding ASND
RCM
ACA
JT
Barclays's ASND Position: Q2 2026 in Review
Barclays increased its Ascendis Pharma A/S (ASND) stake by 116% in Q2 2026, buying an estimated $9.6M and bringing the position to 76,540 shares worth $20.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1121.
Barclays first reported a position in ASND in Q3 2017 and has held it in 36 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Barclays held 76,540 shares of Ascendis Pharma A/S worth $20.4M as of Q2 2026.
- Barclays bought 41,087 Ascendis Pharma A/S shares in Q2 2026, an estimated $9.6M.
- Ascendis Pharma A/S made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1121 holding.
- Barclays first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 36 quarters since.
- 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.